Myocardial Infarction
📧 Sign up to get email alerts when something new happens for Myocardial Infarction.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2007-03-29Clinical Trial Update: Non-Invasive Ventilation in Pulmonary Edema [Phase 4]
Phase 4 clinical trial update on non-invasive ventilation for pulmonary edema and myocardial infarction; the study has completed.
-
FDA label_change · 2007-03-14FDA Approved: TOPROL XL — Supplemental Application (Melinta Therapeutics, LLC)
FDA approved a supplemental application for TOPROL XL (metoprolol succinate) submitted by Melinta Therapeutics, LLC.
-
FDA approval · 2007-03-01FDA Approved: ATENOLOL — Supplemental Application (Zydus Lifesciences Limited)
The FDA approved a supplemental application for Atenolol from Zydus Lifesciences Limited under an ANDA. The action approves changes to the g…
-
CLINICAL_TRIALS research · 2007-03-01Clinical Trial Update: Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating vitamin E for preventing cardiovascular complications in diabetic patients; the study is termina…
-
FDA approval · 2007-02-13FDA Approved: LISINOPRIL — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA supplemental approval for Camber Pharmaceuticals' lisinopril generic under ANDA075903. Lisinopril is used to treat hypertension, heart f…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2007-02-06FDA Approved: LISINOPRIL — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for lisinopril from Aurobindo Pharma Limited, authorizing a generic lisinopril product under an ANDA…
-
FDA approval · 2007-01-30FDA Approved: LISINOPRIL — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for lisinopril filed by Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2007-01-27FDA Approved: ATENOLOL — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Atenolol submitted by Zydus Lifesciences Limited.
-
CLINICAL_TRIALS research · 2007-01-23Clinical Trial Update: Use of ECMO in Acute MI
Clinical trial update on using ECMO in patients with acute myocardial infarction (AMI).
-
CLINICAL_TRIALS research · 2007-01-17Clinical Trial Update: Anti-Restenosis After AMI by Erythropoietin [Phase 4]
Phase 4 clinical trial evaluating erythropoietin to prevent restenosis after an acute myocardial infarction. Sponsor: Kyoto Prefectural Univ…
-
CLINICAL_TRIALS trial_result · 2007-01-17Clinical Trial Update: Polish-Italian-Hungarian RAndomized ThrombEctomy Trial [Phase 4]
A Phase 4 randomized thrombectomy trial for myocardial infarction conducted by a Polish-Italian-Hungarian collaboration; the current status …
-
FDA approval · 2006-12-27FDA Approved: ATENOLOL — Original Application (Ipca Laboratories Limited)
FDA approved the original ANDA for Atenolol by Ipca Laboratories Limited, authorizing a generic atenolol product. Atenolol is used for condi…
-
FDA label_change · 2006-12-20FDA Approved: COREG — Supplemental Application (Waylis Therapeutics LLC)
The FDA approved a supplemental application for COREG (carvedilol) submitted by Waylis Therapeutics LLC. The approval indicates an update to…
-
CLINICAL_TRIALS trial_result · 2006-12-04Clinical Trial Update: Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction. [Phase 4]
Phase 4 clinical trial update reports that thrombus aspiration before standard primary angioplasty improves myocardial reperfusion in acute …
-
CLINICAL_TRIALS trial_result · 2006-11-29Clinical Trial Update: A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention [Phase 2]
Phase 2 clinical trial update of INO-1001, a PARP inhibitor, in acute myocardial infarction patients undergoing primary percutaneous coronar…
-
CLINICAL_TRIALS trial_result · 2006-11-17Clinical Trial Update: CD133+ Autologous Cells After Myocardial Infarction [Phase 1, Phase 2]
This document provides an update on a Phase 1/2 trial evaluating CD133+ autologous cell therapy after acute myocardial infarction. The trial…
-
CLINICAL_TRIALS research · 2006-11-01Clinical Trial Update: Stem Cell Mobilization by G-CSF Post Myocardial Infarction to Promote Myocyte Repair [Phase 2, Phase 3]
A clinical trial update for using G-CSF to mobilize stem cells after myocardial infarction to promote myocyte repair, with Phase 2 and Phase…
-
CLINICAL_TRIALS trial_result · 2006-10-19Clinical Trial Update: Intracoronary Stem Cells in Large Myocardial Infarction [Phase 2]
Phase 2 clinical trial investigating intracoronary stem cells for large myocardial infarction; the current status of the trial is unknown.
-
CLINICAL_TRIALS trial_result · 2006-10-12Clinical Trial Update: Comparison of Anti-Ischemic Drug Therapy and Percutaneous Transluminal Angioplasty After Myocardial Infarction [NA]
A completed clinical trial comparing anti-ischemic drug therapy with percutaneous transluminal angioplasty after myocardial infarction.
-
FDA approval · 2006-10-04FDA Approved: HEPARIN SODIUM — Supplemental Application (Civica, Inc.)
The FDA approved Civica, Inc.'s supplemental application for Heparin Sodium. This action updates the product labeling as part of the NDA 017…
-
CLINICAL_TRIALS trial_result · 2006-10-03Clinical Trial Update: ARISE - Aggressive Reduction of Inflammation Stops Events [Phase 3]
Phase 3 trial ARISE evaluating aggressive reduction of inflammation to stop events in patients with atherosclerosis and coronary artery dise…
-
FDA approval · 2006-09-13FDA Approved: ATENOLOL — Original Application (Rising Pharma Holdings, Inc.)
FDA approved Atenolol as a generic under ANDA077443 from Rising Pharma Holdings, Inc. for the treatment of hypertension, angina pectoris, an…
-
FDA approval · 2006-08-17FDA Approved: PLAVIX — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Plavix (clopidogrel) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2006-08-08FDA Approved: LISINOPRIL — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for lisinopril from Quallent Pharmaceuticals Health LLC.
-
CLINICAL_TRIALS trial_result · 2006-08-04Clinical Trial Update: A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack [Phase 3]
A Phase 3 study evaluating nitric oxide reduction in patients with cardiogenic shock following a heart attack was terminated.